News · Heart & Metabolic
A weight-loss drug cleared liver fat in 84% of patients
A Nature Medicine phase 3 trial of 216 adults found survodutide cut liver fat by at least 30% in 84.2% of those treated, against 24.3% on placebo, alongside 12.2% weight loss.
Based on a peer-reviewed phase 3 trial in Nature Medicine
- The SYNCHRONIZE-MASLD phase 3 trial randomized 216 adults with obesity and at-risk fatty liver disease, publishing in Nature Medicine.
- Survodutide is a dual agonist, acting on both the glucagon receptor and the GLP-1 receptor, given as a weekly injection.
- Participants got survodutide 6.0 mg (146 people) or placebo (70) for 48 weeks, randomized 2 to 1.
- 84.2% of treated patients had at least a 30% reduction in liver fat, against 24.3% on placebo.
- Mean body weight fell 12.2% with survodutide and 1.0% with placebo.
- The most frequent side effects were gastrointestinal, mostly during dose escalation, and generally mild to moderate.
- The authors list the limitations themselves: 48 weeks is short, and recruitment covered only the United States and Spain.
- Liver fat measured by scan is a surrogate. The trial did not test whether cirrhosis or liver failure become less likely.
Fatty liver disease now affects roughly a third of adults worldwide and, until very recently, had no approved drug treatment at all. A phase 3 trial in Nature Medicine reports one clearing liver fat in most of the people who took it.
Among 216 adults with obesity and at-risk fatty liver disease, 84.2% of survodutide-treated patients versus 24.3% of placebo-treated patients had a 30% or greater reduction in liver fat content.
The drug, and why the second receptor matters
Survodutide is a glucagon receptor and glucagon-like peptide-1 receptor dual agonist under investigation for treating obesity and related diseases. The GLP-1 half is familiar from semaglutide and tirzepatide.
The glucagon half is the point of difference. Glucagon acts directly on the liver and raises energy expenditure, which is the mechanistic argument for using this particular drug against a liver condition rather than relying on weight loss alone.
How the trial was built
Participants were adults with obesity, defined as a body mass index of 30 or above, or 27 with at least one obesity complication, plus at-risk fatty liver disease established either by non-invasive tests or biopsy-confirmed inflammation.
They were randomized 2 to 1 and treated with once-weekly subcutaneous injections of survodutide 6.0 mg, 146 people, or placebo, 70 people, for 48 weeks. The trial had co-primary endpoints: liver fat reduction and percentage change in body weight, both measured from baseline to week 48.
Both were met.
What changed
The liver result is the headline, and it survives a stricter reading. Under the more conservative of the two estimates reported, the gap narrowed but held, at 68.5% versus 28.6%.
Weight moved in parallel. Mean percentage change in body weight was -12.2% with survodutide and -1.0% with placebo.
Side effects were unremarkable for the class: mostly gastrointestinal, mostly during dose escalation, and generally mild to moderate.
The gap between fat and disease
Here is where enthusiasm needs restraining. Liver fat measured on a scan is a surrogate. It correlates with the disease process, and reducing it is presumably good, but the outcomes that matter are cirrhosis, liver failure, transplant and death. None of those were measured.
The confounding is also unresolved. Participants lost 12.2% of their body weight, and weight loss of that size reduces liver fat on its own. Nothing here isolates a specific liver effect from the general effect of being substantially lighter.
The authors are unusually forthcoming about the rest, listing the limitations themselves: short trial duration at 48 weeks, and limited global reach, with participants recruited in the United States and Spain.
What it establishes
Within those bounds, the finding is solid. This is a phase 3 randomized, double-blind, placebo-controlled trial that met both of its co-primary endpoints, in a condition that had nothing to offer patients five years ago.
The authors’ own summary stays inside the data: survodutide treatment was statistically and clinically superior to placebo for reductions in liver fat content and body weight.
For anyone told they have a fatty liver, the honest position is that treatments are arriving, that they are the same drugs transforming obesity care, and that nobody yet knows whether shifting the fat on the scan shifts the ending.
People also ask
What is MASLD, and why does it matter?
Metabolic dysfunction-associated steatotic liver disease is fat accumulating in the liver alongside metabolic problems such as obesity or diabetes. It is now the most common liver condition worldwide. Most people with it are fine, but a subset progress to inflammation, scarring and eventually cirrhosis or liver cancer. Until recently there were no approved drug treatments, which is why results like this attract attention.
How is survodutide different from semaglutide?
Semaglutide acts on the GLP-1 receptor. Survodutide is a dual agonist, hitting both the glucagon receptor and the GLP-1 receptor. The glucagon component is thought to increase energy expenditure and act directly on the liver, which is the theoretical reason it might suit fatty liver disease specifically rather than working only through weight loss.
Is losing liver fat the same as curing liver disease?
No, and this is the key limitation. The trial's endpoint was liver fat content measured by MRI, which is a surrogate marker: it tracks with disease but is not the disease outcome patients care about. Whether this translates into less scarring, fewer cirrhosis cases or longer life needs longer trials with harder endpoints. A 48-week fat reduction is an encouraging start, not a demonstrated cure.
Is the liver benefit just the weight loss?
The trial cannot separate them, because the same people lost 12.2% of body weight and cleared liver fat. Weight loss alone is known to reduce liver fat substantially. Whether the glucagon component adds anything beyond that would require comparing survodutide against another drug producing equivalent weight loss, which this trial did not do.
How bad were the side effects?
In line with the drug class. The most frequently reported adverse events were gastrointestinal, commonly occurring during dose escalation, and generally of mild-to-moderate severity. That means nausea, vomiting and diarrhea, concentrated in the weeks when the dose is being raised. The trial reports no unexpected safety signal, though 216 people over 48 weeks cannot detect rare harms.
References
- Kaplan LM, Startseva E, le Roux CW, et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nature Medicine (2026).
- National Institute of Diabetes and Digestive and Kidney Diseases. Definition & Facts of NAFLD & NASH.